Recce Pharmaceuticals (ASX:RCE) is a clinical-stage biotech company developing its own proprietary synthetic anti-infectives (RECCE 327, RECCE 529) for antibiotic-resistant bacterial and viral infections. They have an in-house pilot manufacturing facility in Macquarie Park, Sydney for their own compounds only -- they are NOT a contract manufacturer (CDMO/CMO). They conduct clinical trials (Phase I-III) for their own drug pipeline. The FDA registration data and approved products listed in the regulatory summary likely belong to a different entity sharing the FEI numbers, not this clinical-stage company.
proprietary synthetic anti-infectives, anti-microbial resistance, automated GMP manufacturing process, topical and IV formulations for own pipeline
1 site worldwide
No certifications on file yet.
No reviews available yet.
No documents available.